Doctor’s Passport

Find your next topic

Explore the current textbook

Available drafts · Clinical review pending
Membership
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Full textbook

Spontaneous intracerebral haemorrhage

Diagnose non-traumatic intracerebral haemorrhage rapidly, identify haematoma expansion and secondary causes, deliver cause-appropriate acute care, and understand the limits of blood-pressure, reversal, prognostic and surgical rules.

Saved on this device
!
Haemorrhagic stroke is time critical

Sudden focal deficit, headache, vomiting, seizure or reduced consciousness may be spontaneous ICH. Expansion, intraventricular extension, hydrocephalus and posterior-fossa compression can produce rapid deterioration.

Action: Activate the stroke and neurocritical pathway, stabilise airway and circulation, obtain immediate non-contrast CT, record onset and antithrombotic exposure, use a smooth cause- and severity-matched blood-pressure plan, and seek urgent stroke, neurosurgical and haematology input where indicated.

Open the sections you need. The overview is shown first.
01Core principlesThe concepts and mechanisms needed to understand the subject.

Primary spontaneous ICH commonly arises from rupture of small arteries affected by hypertensive arteriopathy or cerebral amyloid angiopathy. Deep perforator territories include basal ganglia, thalamus, pons and cerebellum; amyloid angiopathy more often produces lobar haemorrhage in older adults. Secondary causes include arteriovenous malformation, aneurysm, dural fistula, cavernoma, cerebral venous thrombosis, tumour, vasculitis, sympathomimetic drugs and haemostatic disorders. Location suggests possibilities but never proves aetiology.

Injury develops through the initial mechanical disruption, haematoma expansion, surrounding oedema, inflammation, intraventricular blood and raised pressure. Expansion is most likely early, making onset time, antithrombotic status, blood pressure and repeat examination consequential. A small strategically located pontine bleed can be devastating, while a larger lobar collection may initially spare consciousness; volume alone cannot replace anatomy and trajectory.

Evidence contains important boundaries. The 2025 ESO/EANS guideline supports early smooth blood-pressure reduction most clearly in minor-to-moderate ICH below 30 mL, while cautioning about very high presenting pressure, large clots, planned evacuation and excessive falls. Its reversal recommendations are drug-specific and not equivalent to UK authorisation or commissioning. Surgery may be life-saving for obstructive hydrocephalus or selected cerebellar disease, but routine open evacuation for every supratentorial ICH is not justified.

Key points

  • Spontaneous ICH is bleeding into brain parenchyma without trauma; keep it separate from traumatic contusion, aneurysmal SAH, haemorrhagic transformation of infarction and extra-axial bleeding.
  • Non-contrast CT confirms blood and defines location, volume, intraventricular extension, hydrocephalus and mass effect. Repeat CT is driven by early expansion risk and any neurological decline.
  • Deep basal-ganglia, thalamic, pontine or cerebellar bleeding often reflects small-vessel arteriopathy; lobar bleeding broadens the differential to cerebral amyloid angiopathy, macrovascular lesions, tumour, venous disease and drug-associated causes.
  • NICE says to consider rapid lowering when acute ICH presents within 6 hours with systolic BP 150–220 mmHg: aim for 140 mmHg or lower, but do not drop more than 60 mmHg in the first treatment hour. Separately, ESO/EANS suggests below 140 mmHg within 6 hours only for adults with minor or moderate ICH under 30 mL, avoiding a fall over 70 mmHg or active reduction below 110 mmHg and using caution above 220 mmHg, with larger clots or planned evacuation.
  • Stop antithrombotics and use an agent-specific specialist pathway: VKA ICH needs four-factor PCC plus IV vitamin K and adult dabigatran life-threatening bleeding uses idarucizumab 5 g. Do not use andexanet routinely class-wide: its adult licence covers life-threatening or uncontrolled apixaban/rivaroxaban bleeding, not edoxaban; NICE TA697 commissioning is restricted to gastrointestinal bleeding, and BSH April 2026 warns that thrombotic and stroke risk may outweigh benefit.
  • Surgery is diagnosis-, location- and patient-specific. Hydrocephalus with reduced consciousness supports EVD; 2025 ESO/EANS suggests cerebellar evacuation above 15 mL for survival, while supratentorial strategies carry weaker, selected evidence.
02Mechanisms and patternsImportant relationships and how to distinguish them.
Recognise the syndromeRed flag

Sudden hemiparesis, hemisensory loss, aphasia, neglect, ataxia, vertigo, gaze deviation or dysarthria can resemble ischaemic stroke. Headache, vomiting, seizure and reduced consciousness increase suspicion of haemorrhage but imaging is required.

Establish time and trajectoryRed flag

Record last known well, witnessed onset, pre-hospital change, GCS and NIHSS-compatible findings. New deterioration after the first scan may represent expansion, intraventricular extension, hydrocephalus, seizure, hypoxia or systemic instability.

Map location clinically

Putaminal haemorrhage often causes contralateral weakness with gaze toward the lesion; thalamic disease may cause sensory loss and ocular signs; pontine bleeding can produce coma and small reactive pupils; cerebellar bleeding causes headache, vomiting, ataxia and brainstem compression. These patterns overlap.

Seek secondary-cause clues

Young age, no hypertension, lobar or unusual location, prodromal headache, malignancy, infection, pregnancy, stimulant exposure or a vascular bruit lowers the threshold for CTA, venography, MRI or catheter angiography.

Define haemostatic context

Identify vitamin K antagonist, direct thrombin inhibitor, factor Xa inhibitor, heparin and antiplatelet therapy separately. Record dose, last ingestion, renal function, indication and relevant assays; do not wait for a complete panel before specialist reversal action.

Avoid premature prognosis

Age, GCS, volume, infratentorial origin and intraventricular extension inform the ICH score, but calibration varies and historical cohorts predate current stroke-unit care. Reassess after stabilisation before using prognosis in shared decisions.

Red flags requiring action

  • Declining consciousness, worsening focal deficit, new anisocoria, repeated vomiting, posturing or abnormal respiration suggests expansion, hydrocephalus or herniation and requires immediate reassessment and repeat imaging.
  • Cerebellar haemorrhage with brainstem compression, obstructive hydrocephalus or neurological deterioration is a neurosurgical emergency even when supratentorial rules seem reassuring.
  • Intraventricular extension plus hydrocephalus contributing to impaired consciousness may require emergency external ventricular drainage; the drain treats CSF obstruction rather than the parenchymal clot itself.
  • Anticoagulant-associated ICH requires immediate identification of exact agent, last dose and renal function. Drug-specific reversal must follow current product status, specialist guidance and UK jurisdiction or local availability.
  • Young age, lobar or posterior-fossa location, absent small-vessel-disease markers, vascular imaging abnormality, cancer, pregnancy or venous thrombosis clues increase suspicion of a secondary cause.
  • A high ICH score must not be used alone to limit active treatment or make an early irreversible prognosis; the score is a descriptor built from historical cohorts.
03Interpreting evidenceInformation, measurements and their limitations.
Reasoning sequence

Consider the information, its meaning and its limitations before deciding what follows.

  1. 01
    Immediate non-contrast CT head
    Why
    Differentiate ICH from ischaemic stroke and define the anatomical threat.
    Interpretation and limitations
    Describe location, estimated volume, intraventricular extension, hydrocephalus, midline shift, basal cisterns and signs of herniation. Look for subarachnoid blood, mass or venous pattern that redirects the diagnosis.
  2. 02
    Repeat non-contrast CT
    Why
    Detect haematoma expansion or new hydrocephalus during the high-risk early course and after deterioration.
    Interpretation and limitations
    Compare volume, ventricular blood, shift and cisterns with the baseline scan. Neurological decline should prompt urgent repeat imaging even if the initial clot appeared small.
  3. 03
    CT angiography with cause-directed MRI, venography or catheter angiography
    Why
    Find a macrovascular, venous, neoplastic or other secondary cause in an appropriate phenotype.
    Interpretation and limitations
    The DIAGRAM approach combines age, location, small-vessel-disease signs and CTA result to estimate macrovascular probability, but external validation was only moderate before CTA. A negative test does not end investigation when suspicion remains high.
  4. 04
    Full blood count, glucose, electrolytes, renal and liver function, PT/INR, APTT and agent-relevant assays
    Why
    Identify physiological mimics, organ dysfunction and haemostatic factors that alter treatment.
    Interpretation and limitations
    INR guides vitamin K antagonist reversal, but PT or APTT cannot reliably quantify every direct anticoagulant. Interpret a drug level or anti-Xa assay only with its calibrated agent, sampling time and local laboratory capability.
  5. 05
    Serial neurological and physiological monitoring
    Why
    Recognise expansion, seizure, pressure crisis and complications of blood-pressure or haemostatic treatment.
    Interpretation and limitations
    Trend GCS components, focal signs, pupils, blood pressure and variability, oxygenation, temperature and glucose. A smooth target trajectory matters; hypotension, a large rapid fall or worsening examination triggers immediate review.
04Applied reasoningWorked examples connecting principles to decisions.
01Worked case: first-hour ICH careAcute focal deficit with CT-confirmed ICHAn adult presents within hours with spontaneous parenchymal haemorrhage and no trauma.
  1. 1Activate stroke and neurocritical teams, stabilise airway and oxygenation, obtain immediate CT, record exact onset, GCS, focal deficit, baseline function, blood pressure and all antithrombotic exposure.
  2. 2Classify location, volume, ventricular extension, hydrocephalus and mass effect; send core bloods, stop antithrombotics and seek haematology input. Use four-factor PCC plus IV vitamin K for VKA-associated ICH and idarucizumab 5 g for adult dabigatran-associated life-threatening bleeding. For factor-Xa exposure, make an agent-specific specialist decision: andexanet is licensed in adults for life-threatening or uncontrolled apixaban/rivaroxaban bleeding, not edoxaban; NICE TA697 commissioning is restricted to gastrointestinal bleeding, and the April 2026 BSH position warns that thrombosis and ischaemic-stroke risk may outweigh benefit, so it is not routine class-wide ICH reversal.
  3. 3Apply the exact NICE blood-pressure rule only when its conditions fit: consider rapid lowering for acute ICH presenting within 6 hours with systolic BP 150–220 mmHg, aiming for 140 mmHg or lower without a fall greater than 60 mmHg in the first treatment hour. Separately, ESO/EANS suggests below 140 mmHg within 6 hours for adults with minor or moderate ICH under 30 mL, avoiding a fall over 70 mmHg or active reduction below 110 mmHg and using caution above 220 mmHg, in larger clots or when evacuation is planned.
  4. 4Discuss immediately with neurosurgery for posterior-fossa bleeding, hydrocephalus with impaired consciousness, herniation, progressive decline or a potentially treatable selected supratentorial lesion.
  5. 5Repeat examination and CT according to early risk and any change, then investigate the cause through vascular or MRI pathways when phenotype warrants it.
02Neurosurgical emergencyIVH, hydrocephalus or cerebellar compressionICH extends into ventricles with obstructive hydrocephalus and reduced consciousness, or a cerebellar clot causes brainstem compression or deterioration.
  1. 1Escalate immediately to neurosurgery and neurocritical care while protecting airway, perfusion and ventilation; repeat CT if the clinical state has changed.
  2. 2Use EVD for intraventricular blood with hydrocephalus contributing to impaired consciousness; in cerebellar ICH, assess clot volume, compression and the need for evacuation rather than relying on drainage alone.
  3. 3Continue cause-specific haemostasis and monitoring because CSF diversion does not stop the original bleeding source.
03Aetiology pathwayPossible secondary ICHAge, location, history or CT features are atypical for small-vessel arteriopathy.
  1. 1Perform CTA promptly when appropriate and select venography, MRI or catheter angiography with neuroradiology based on suspected malformation, venous thrombosis, tumour or other cause.
  2. 2If initial vascular imaging is negative but pre-test probability remains high, agree delayed or alternative imaging rather than labelling the event primary by exclusion.
  3. 3Carry the established cause into secondary prevention, genetic or family assessment and follow-up rather than defaulting every survivor to a hypertension-only plan.
05Checking understandingVerify the reasoning, revisit uncertainties and apply feedback.
  • Use frequent GCS, pupil and focal-neurology checks with continuous cardiorespiratory monitoring during the acute phase.
  • Chart blood pressure continuously or at short intervals, including treatment start, rate of fall, variability and any renal or neurological adverse effect.
  • Repeat CT for clinical decline and according to the stroke service’s expansion-risk protocol; compare ventricular extension and hydrocephalus as well as parenchymal volume.
  • After any reversal strategy, monitor haemostasis, thrombosis, renal function and the need and timing for restarting thromboprophylaxis or long-term antithrombotics.
  • Screen swallowing before oral intake, prevent aspiration and immobility complications, manage fever and glucose, and begin multidisciplinary rehabilitation when stable.
06Special situationsVariants, exceptions and circumstances that change the usual approach.

Location guides, not proves

A deep clot supports hypertensive arteriopathy and a lobar clot supports amyloid or secondary disease, but vascular and drug-related causes can occur in either.

Expansion is a process

A CT is one time point. Worsening deficit or consciousness after imaging demands a search for growth, IVH, hydrocephalus and seizure.

Pressure targets have edges

Trial populations mainly had minor-to-moderate volumes. Severe, very large, very hypertensive or operative patients need individual perfusion-aware decisions.

EVD has one job

Ventricular drainage can relieve obstructive hydrocephalus; it neither evacuates a parenchymal clot nor guarantees recovery.

A score cannot set a ceiling

Prognostic scores communicate severity and support audit, but early self-fulfilling treatment limitation can distort their apparent accuracy.

07Common pitfallsFrequent interpretation and management errors.
  1. 01

    Calling an ICH hypertensive from location alone without considering macrovascular, venous, tumour and drug-associated causes.

  2. 02

    Using one blood-pressure number without stating onset time, initial SBP, haematoma volume, perfusion and surgical context.

  3. 03

    Assuming a normal PT or APTT excludes clinically important direct anticoagulant activity.

  4. 04

    Treating EVD as complete management of intraventricular extension or cerebellar mass effect.

  5. 05

    Applying traumatic acute SDH or aneurysmal SAH operative and medical rules to spontaneous ICH.

  6. 06

    Using the ICH score alone to withdraw active care or deny neurosurgical review.

Practice

Two practice questions

Question 1 of 20 correct
NeurosurgeryOriginal SBA

Clinical decline after the first CT

A patient with a small spontaneous thalamic ICH becomes more drowsy two hours after the initial scan and develops repeated vomiting. What is the best next step?

Sources and review status5 sources · checked 13 Sept 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 13 Sept 2026; clinical approval remains outstanding.

  • NICE NG128 Stroke and TIA recommendationsCurrent recommendation body and March 2026 surveillance status checked 13 September 2026; acute ICH blood-pressure, monitoring and anticoagulation-reversal headings reviewed. England/Wales NICE context; drug links and commissioning status require separate current verification.
  • ESO/EANS guideline on spontaneous intracerebral haemorrhagePublished online May 2025; diagnostic assessment, blood-pressure PICO, haemostasis PICO, surgery, EVD, care-bundle and prognostic-score sections read 13 September 2026. Adults with spontaneous ICH; European professional guideline, not UK commissioning or product-access authority.
  • BSH andexanet alfa position statementPublished 25 April 2026; full clinical body and recommendations read in the shared E2 packet. UK professional position: increased thrombosis, especially ischaemic stroke, may outweigh benefit; this does not revoke the medicine licence.
  • UK idarucizumab and andexanet product informationPraxbind SmPC updated January 2025 and Ondexxya SmPC updated March 2026, sections 4.1 to 4.4 read in the shared E2 packet. Adult licensed indications and idarucizumab 5 g supported; https://www.medicines.org.uk/emc/product/10933/smpc confirms andexanet is licensed for life-threatening or uncontrolled apixaban/rivaroxaban bleeding, not edoxaban or universal urgent-surgery reversal.
  • NICE TA1029 terminated intracranial appraisalAdvice dated 15 January 2025 read in the NCBI Bookshelf mirror. The company declined an evidence submission, so NICE made no intracranial recommendation and permits rational local NHS decisions; this is neither prohibition nor licence withdrawal.
Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom